Society of Hematologic Oncology

Society of Hematologic Oncology SOHO is the only global society dedicated to the research & treatment of hematologic malignancies. Join SOHO for FREE today at soho.click/join.

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. SOHO is led by a Board of Directors with six voting members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively.

“Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Fifth Annual Meeting is scheduled for September 13-16, 2017 at the Westin Galleria and Oaks in Houston, Texas. The society expects more than 1,000 physicians and related professionals to attend the 3.5-day event. (go to soho2017.com for more information and registration).

Join us on March 18 to discuss T-cell engagers & considerations for broad adoption across hematology & oncology with Drs...
03/16/2026

Join us on March 18 to discuss T-cell engagers & considerations for broad adoption across hematology & oncology with Drs. Jeffrey Matous & Loretta Nastoupil. Register for free at https://soho.click/community-oncology-series

Watch our interview with Drs. Zheng and Bona on financial toxicity in pediatric ALL from
03/16/2026

Watch our interview with Drs. Zheng and Bona on financial toxicity in pediatric ALL from

Daniel Zheng, MD, a pediatric oncologist at the Children's Hospital of Philadelphia, and Kira Bona, MD, a pediatric oncologist at Dana-Farber Boston Children...

China NMPA approves pirtobrutinib in relapsed/refractory CLL/SLL
03/10/2026

China NMPA approves pirtobrutinib in relapsed/refractory CLL/SLL

The China National Medical Products Administration (NMPA) has approved pirtobrutinib (Jaypirca), a noncovalent BTK inhibitor, for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) after at least one prior line of therapy including a BTK i...

FDA accepts NDA for iberdomide in relapsed/refractory myeloma
03/09/2026

FDA accepts NDA for iberdomide in relapsed/refractory myeloma

The US Food and Drug Administration (FDA) accepted a new drug application (NDA) for iberdomide in combination with daratumumab (Darzalex) and dexamethasone for adult patients with relapsed or refractory multiple myeloma Iberdomide is the first in a new class of medicines called CELLMoD agents, which...

New therapies push UK registries into central role
03/07/2026

New therapies push UK registries into central role

The future of registries in the UK came into focus during an afternoon session at SOHO UK with Priyanka Mehta, MBBS, MD, FRCP, FRCPath, a consultant haematologist at University Hospitals of Bristol and Weston NHS Trust, leading a discussion on the recently launched MyeCare registry for acute myeloid...

FDA approves teclistamab combo in relapsed myeloma
03/06/2026

FDA approves teclistamab combo in relapsed myeloma

The United States Food and Drug Administration (FDA) approved teclistamab-cqyv (TECVAYLI®) plus daratumumab and hyaluronidase-fihj (DARZALEX FASPRO®) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasom...

At the historic Royal College of Physicians in London, is underway.
03/03/2026

At the historic Royal College of Physicians in London, is underway.

SOHO UK starts March 3 in London; the 1st for our UK colleagues. Prof. Charlie Craddock says the meeting will cover all ...
03/02/2026

SOHO UK starts March 3 in London; the 1st for our UK colleagues. Prof. Charlie Craddock says the meeting will cover all of haemato-oncology & explore new important areas such as the role of registries and translational medicine.

The first SOHO UK meeting launches in London with a strong emphasis on understanding the pace of change across haematologic oncology and supporting the next generation of clinicians. The inaugural SOHO UK meeting opens 3 March at the Royal College of Physicians in London, bringing together clinician...

FDA clears IND application for TBS-2025 in AML
02/26/2026

FDA clears IND application for TBS-2025 in AML

The Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for TBS-2025, a novel VISTA-inhibiting antibody, for the treatment of relapsed or refractory acute myeloid leukemia (AML). The therapy will be studied in combination with a menin inhibitor for patients....

Liso-cel shows good 3-year response, safety results in patients with R/R follicular lymphoma
02/25/2026

Liso-cel shows good 3-year response, safety results in patients with R/R follicular lymphoma

Lisocabtagene maraleucel (liso-cel) showed high response rates and favorable safety in patients with relapsed or refractory follicular lymphoma (R/R FL), according to results from the open-label, pivotal TRANSCEND FL study published in Transplantation and Cellular Therapy. The paper reports on three...

Address

The Woodlands, TX
77393

Opening Hours

Monday 8am - 6pm
Tuesday 8am - 6pm
Wednesday 8am - 6pm
Thursday 8am - 6pm
Friday 8am - 6pm

Telephone

+12813647387

Website

http://soho.click/2026, http://sohoinsider.com/, http://sohoonline.org/

Alerts

Be the first to know and let us send you an email when Society of Hematologic Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Society of Hematologic Oncology:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

About the Society

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders. Since that time, nearly 3,000 members have joined the society from around the globe. SOHO is led by a Board of Directors with eight voting members. In addition, an outstanding group of clinician-scientists have been assembled to serve on the Steering Committee to provide guidance and direction in the continued development of SOHO. Two additional committees, Scientific and Education, are responsible for abstract review and the scientific program of the annual meetings, respectively. “Clinical Lymphoma, Myeloma & Leukemia,” a peer-reviewed journal published by Elsevier, is the official journal of SOHO. It is available online free-of-charge to SOHO members and at a discounted rate in printed form (click the 'Sign Up' button to become a SOHO member). The SOHO Sixth Annual Meeting is scheduled for September 12-15, 2018 at the Hilton Americas-Houston in Houston, Texas. The society expects approximately 1,200 physicians and related professionals to attend the 3.5-day event. (go to soho2018.org for more information, abstract submissions and registration).